Parent company Legend Holdings contributed 25% of the total as early-stage investment arm Legend Star closed its fourth renminbi-denominated fund.

The small molecule cancer drug developer has launched with series A funding from investors including Partners HealthCare Innovation.

Evonik and Mectalent have exited the bone implant developer in an acquisition by Globus Medical that follows nearly $12m in funding.

The cancer and fibrosis drug developer's series D round was co-led by investors including Walvax Biotechnology and a fund management vehicle for Sunshine Insurance.

Takeda Ventures was among the investors as the cellular therapeutics developer launched with a round co-led by RA Capital Management and Atlas Venture.

Legend Capital has contributed to an eight-figure dollar round for the neurological surgery device provider that was led by Hillhouse Capital.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Sarepta Therapeutics provided $15m in a series A round for the company, which is advancing University of Florida research.

Incubated by Vision Institute, the retinal disease gene therapy developer has secured $52.8m in a round co-led by UPMC Enterprises.

QUB spinout ProAxsis has been fully acquired by NetScientific, which previously backed the company’s sole funding round in 2014.